News & media

Attempting to target the tumor microenvironment leads the way to an array of potential targetable pathways in the disease..

According to the researchers, attempting to target the tumor microenvironment leads the way to an…

Continue reading

Medical specialist says Pharmac ‘wish list’ is a ‘necessity list’

Health expert discusses Pharmac's funding option list.

Continue reading

CLL Advocates Newsletter Issue 10

Welcome to issue 10 of the CLL Advocates newsletter.

Continue reading

Exploring Why Venetoclax and Ibrutinib Have Synergy in the CLL Population

William G. Wierda, MD, PhD, D. B. Lane Cancer Research Distinguished Professor, section chief of…

Continue reading

CLL Advocates Newsletter Issue 9

Welcome to issue 8 of the CLL Advocates newsletter.

Continue reading

Higher Overall Response Rates Observed When Adding Ublituximab to Ibrutinib Treatment for CLL

The new combination treatment of ublituximab plus ibrutinib resulted in a higher overall response…

Continue reading

Webinar: The current CLL treatment landscape and advocating for your care

This 3-hour program will take you through the current treatment landscape of CLL, including the…

Continue reading

CLL Can Leave You Immunocompromised. Here’s How to Manage

Your bone marrow plays an important role in your body. It produces versatile stem cells that become…

Continue reading

The epic battle with cancer’s ‘Death Star’

Forty years after the mutant genes that cause the deadliest cancers were discovered, drugs that…

Continue reading

R. Gregory BD, discusses outcomes for patients with chronic lymphocytic leukemia and COVID-19.

R. Gregory Bociek, MD, an associate professor of internal medicine, Division of Oncology and…

Continue reading

CLL Advocates Newsletter Issue 8

Welcome to issue 8 of the CLL Advocates newsletter.

Continue reading

Limited Following of Best Practices for CLL Observed in the Real-World Setting

Anthony Mato, MD, MSCE, discusses an observational registry study of real-world prognostic…

Continue reading

Supplements, My Treatment Approach: Chronic Lymphocytic Leukemia, Volume 1, Issue 1

Tara Graff, DO, highlights active areas of exploration that are generating excitement in chronic…

Continue reading

CLL Advocates Newsletter Issue 7

Welcome to issue 7 of the CLL Advocates newsletter. This month's newsletter shares our latest…

Continue reading

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR…

Continue reading

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

Because patients with chronic lymphocytic leukemia (CLL) can sometimes be more susceptible to…

Continue reading

The Treatment Journey of a Patient with CLL

In this episode of the “CURE Talks Cancer” podcast, we spoke with Mark Hoffman, a patient with…

Continue reading

What Is the Outlook for Older Patients with CLL?

The prognosis for patients with chronic lymphocytic leukemia (CLL) has seen recent improvements.

Continue reading

John N. Allan, MD, on Research Coming Out of ASH for CLL

The assistant professor of Medicine in the division of Hematology and Medical Oncology at Weill…

Continue reading

An Analysis of CLL in Adolescents and Young Adults

Most patients diagnosed with chronic lymphocytic leukemia (CLL) are older; the median age at…

Continue reading

Case Study: COVID-19 and the Coexistence of CLL

Many symptoms of SARS-CoV-2 (COVID-19) can be concealed due the coexistence of malignant…

Continue reading

Venclexta PBS listed as first line therapy for CLL patients unfit for chemotherapy

VENCLEXTA plus obinutuzumab is a combination, fixed duration therapy for previously untreated…

Continue reading

ASH 2020 CLL Daily Wrap-Up

Join Patient Power on Tuesday, December 8th at 4pm PT/7pm ET for a live recap of the latest chronic…

Continue reading

CLL and COVID-19: What Should Patients Know About Vaccines?

With the flu season approaching and whispers of a vaccine for COVID-19 in the works, CLL patients…

Continue reading

CLL Advocates NZ Newsletter Issue 6

Welcome to issue 6 of the CLL Advocates newsletter. This month's newsletter shares our latest…

Continue reading

NICE recommends new chemo-free chronic lymphocytic leukaemia treatment

More than 1,000 people each year could benefit from treatment with a combination of venetoclax and…

Continue reading

When and How CLL, SLL Should Be Treated

New treatment options are outperforming the “old-fashioned” chemotherapy regimens for patients with…

Continue reading

Dr. Awan on the Importance of Collaborative Care in CLL

Farrukh Awan, MD, discusses the importance of collaborative care in chronic lymphocytic leukemia.

Continue reading

Different Therapies and Modalities for Treatment of CLL in the Second Line

During a Targeted Oncology Case Based Peer Perspectives event, Danielle Brander, MD, assistant…

Continue reading

CLL Advocates NZ Newsletter Issue 5

Welcome to issue 3 of the CLL Advocates newsletter. This month's newsletter focuses on research and…

Continue reading